logo
23andMe Bankruptcy Affects Marginalized People Who Didn't Share DNA

23andMe Bankruptcy Affects Marginalized People Who Didn't Share DNA

Forbes08-04-2025

There is no rugged individualism in our DNA. Your sequenced DNA can reveal sensitive information ... More about your DNA relatives and people like you.
Sequencing DNA can be empowering. But the recent 23andMe bankruptcy announcement has thrust privacy into the spotlight. Over 15 million people sent their spit to 23andMe, and the DNA they shared may have exposed people who didn't to privacy risks – relatives, perhaps, or people with similar traits or demographic characteristics. As customers with buyer's remorse rush to delete their genetic information (as I've reported here), millions more who don't have an account but whose DNA is linked to those who do have no such recourse. This is especially troubling for people from vulnerable or marginalized groups. The bankruptcy court could appoint a consumer privacy ombudsman to address these concerns, but it seems unlikely.
'I've always questioned how we use individual consent as the lawful basis/condition for the processing of sensitive personal information where there is such a highly asymmetric power dynamic,' writes Samantha Simms in a recent LinkedIn post. The digital lawyer and coach tells me she's particularly concerned about the high numbers of people with Caribbean, African American and Latin American backgrounds who flocked to take the tests 'because the lure of these services is profoundly emotional.'
Once sequenced, DNA can tell you where you came from, but this blueprint of life can also tell you what lies ahead. It can act as an early warning system for disease risk and a roadmap for personalized medicine. So it's no surprise that direct-to-consumer genetic testing is so popular.
Sequenced DNA is also popular with biomedical researchers and pharmaceutical companies, who can use it to link genetic markers to diseases or traits and find cures. For example, researchers have discovered that mutations in the BRCA-1 and BRCA-2 genes signal higher risk for certain cancers like breast cancer. People can now be screened for cancer risk and plan early interventions. With DTC genetic testing, they don't need to wait for a doctor to order tests.
Yet bioethicists, privacy experts and national security experts warn that genetic information can also be misused in dangerous ways. We can't change our DNA if it falls into the wrong hands, unlike other identifiers like a social security number. Greshake Tzovaras, founder of the now-closed OpenSNP project, told 404 Media why he decided to shut down the genetic database he'd created to democratize genomic research. He's seen how genetic databases intended for biomedical research have largely been re-purposed for law enforcement. He cites 'a rise in far-right and other authoritarian governments' as a key driver for deleting the data, which he fears could be used to target individuals or create pseudo-scientific justifications to vilify vulnerable groups.
'Thinking about gender representation, minorities, sexual orientation—23andMe has been working on the whole 'gay gene' thing, it's conceivable that this would at some point in the future become an issue.'
The U.S. Department of Justice has issued a final rule prohibiting the bulk transfer or sale of genomic data to 'countries of concern' like China. The rule extends to the sale of de-identified genomic data because it can be matched with other information to re-identify individuals or used to attack an identifiable population. The risks are significant: the same data used to offer personalized medical treatment could also be weaponized to hyper-target pathogens or bioweapons. But the rule doesn't prevent 23andMe from selling genetic data to buyers in other countries not listed as 'countries of concern.' Nor does it prevent domestic actors from misusing genetic data, as I've discussed here.
Simms does a lot of ancestral research, but she can only trace her story back to 1784. Like many in her community, she longs to understand her history pre-1600s. 'Coming from a people displaced by over 300 years of genocidal chattel slavery, I cannot provide any more precise details of my African ancestry without the aid of a direct-to-consumer DNA testing company, such as 23andMe,' writes Simms on LinkedIn.
'We often carry the ache of a tree without roots. With few photographs, no clear family records, and little oral history preserved, DNA testing offers, albeit partial, answers to an individual's story. The desire to know where we come from is so fundamental that it often outweighs what is seen as the more abstract risks to privacy.'
Despite this, Simms eventually decided against using a DTC genetic testing service over privacy risks and fears about how this data could be used against her community. Breaches, lack of transparency and control, and the possibility of unchecked sharing, data enrichment and profiling by data brokers were top of mind. Now, with the Trump administration's aggressive anti-DEI measures and health secretary RFK Jr. making race-based assertions regarding Black people and COVID, Simms is worried about U.S. government access to genetic data.
Dr. Krystal Tsosie, an Indigenous geneticist-bioethicist and assistant professor at Arizona State University tells me that DTC genetic testing exposes Indigenous communities to unique group privacy risks. Because they tend to be small with shorter generational gaps and larger families, both individuals and tribal communities are re-identifiable. She worries about the stigmatizing effects of genomic profiling; the use of genomic data for research never agreed by those communities; and the loss of Indigenous Data Sovereignty.
Historical misuse of Indigenous data by researchers has caused some tribes to issue moratoria against sharing their genetic data with researchers. In addition, concerns over community privacy have spurred tribal leaders to discourage their members from using DTC genetic testing services. Researchers sometimes fill these gaps using data from other communities as proxies, raising serious accuracy and data quality concerns.
Dr. Tsosie notes that colonially displaced descendants of Native Americans hoping to re-connect with those communities feel compelled to turn to DNA testing for answers. But this reifies it as a biological construct and raises concerns around false claims to Indigeneity. 'We construct belonging and citizenship in ways that do not consider these genetic ancestry tests. So it's not just a matter of what you claim, but it's a matter of who claims you,' says Kim Tallbear in an interview with CBC. Tallbear is Dakota, a professor in the Faculty of Native Studies at the University of Alberta and author of Native American DNA; Tribal Belonging and the False Promise of Genetic Science. She emphasizes that sharing genetic material doesn't constitute lived experience in community, or shared values, beliefs and cultural practices.
It's one thing to accept privacy risks for yourself. When your choices impact others, the risks are amplified. Simms wasn't ready to take a leap of faith with 23andMe, despite its privacy assertions. She feels vindicated. 'Large-scale data breaches, attempts to purchase data by the CEO post-bankruptcy, and an inability to handle deletion requests are not in line with a company that honoured its role to emotionally vulnerable consumers,' she says of 23andMe. 'There is no perfect fix for this imbalance.' Until there is, the safest approach may be not to share at all.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The GLP-1 weight loss debate: Pharmacy benefit leaders weigh in on difficult coverage decisions
The GLP-1 weight loss debate: Pharmacy benefit leaders weigh in on difficult coverage decisions

Business Journals

timean hour ago

  • Business Journals

The GLP-1 weight loss debate: Pharmacy benefit leaders weigh in on difficult coverage decisions

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are a favored treatment for type-2 diabetes but have also become incredibly popular for treating obesity. One in eight U.S. adults have taken GLP-1 medication, according to a KFF Health Tracking Poll, with one in three saying they've heard a lot about them. Usage is growing so fast Goldman Sachs estimates the drugs could push the global market for anti-obesity medications to $100 billion in annual sales by 2030. The challenge for employers is the cost. According to the National Conference of State Legislatures, GLP-1s have an average annual list price of $12,000. Because patients tend to regain weight when they discontinue treatment, the cost of coverage is high. 'GLP-1s are a topic that comes up in almost every client meeting,' said Shanda Harclerode, a pharmacist and pharmacy consultant for Holmes Murphy's employee benefits group. 'Across the board, we're seeing it in the top three drugs in terms of plan spend.' Among Holmes Murphy's employee benefits clients, spending on GLP-1s increased 36% from 2023 to 2024, Harclerode said. The treatments represented 17% of all pharmaceutical spending in 2024 and 4% of medical and pharmacy spending combined. Understanding the market for obesity treatments The appeal for an injectable treatment for obesity is easy to understand, said Nathan Cassin, employee benefits pharmacy director with Holmes Murphy. 'Obesity affects 42% of American adults and that number is rising and these drugs are revolutionary in terms of managing weight,' Cassin said. You have to go back several decades to find new medication releases with this wide of an impact, Cassin said, pointing to Zoloft's approval for mental health conditions in 1991, Lipitor's approval for lowering cholesterol in 1996 and Nexium's approval for reducing stomach acid in 2001. The broad market for obesity treatments has helped spur interest in GLP-1s from many drug manufacturers. There is a robust pipeline of GLP-1 products undergoing clinical trials for obesity treatment and manufacturers are starting to sell the drugs directly to members through telehealth appointments. However, Harclerode said this increased competition will not reduce employers' expenses anytime soon. 'While we may see some of the pricing of the drugs come down as competition increases with new agents coming to market and more competition between the different manufacturers to get their products on the formulary,' she said, 'anticipated increases in utilization are likely going to offset any pricing relief. GLP-1s and similar molecules are currently being studied for a variety of other applications, including Alzheimer's disease, osteoarthritis, and heart failure, significantly expanding their potential use going forward.' Employee benefit strategies for employers Employers are left with difficult choices. Harclerode recommends business leaders start by assessing how GLP-1s fit the needs of their employees. Ask these questions: What is the prevalence of obesity and related conditions within my population? What can we expect in terms of utilization? How much would that utilization cost? Does that cost fit within our employee benefits budget? What is my employee turnover rate? Given that, will our plan realize the potential future benefits that come with weight loss? How important is offering this coverage to our talent attraction and retention efforts? Employers that decide to offer GLP-1 coverage should make sure to design their program in a way that maximizes its effectiveness, Harclerode said. Some clients require people to participate in wellness programs — such as working with a health coach or dietitian — to be eligible for GLP-1 therapies. 'Since these drugs require long-term use for sustained benefits, we want to ensure that if a member stops their GLP-1 therapy, the appropriate behavioral changes have been adopted to maintain the weight loss that was achieved while on the medication,' she said. Because of their popularity, businesses that opt not to cover GLP-1s may want to be transparent with employees about why and what they're doing to support weight loss instead, Harclerode said. They won't be alone. In a 2024 Business Group on Health survey, 67% of large employers reported covering GLP-1s, while only 28% of Holmes Murphy's clients — including many businesses with less than 10,000 people — provide the coverage. 'I don't think there's a one-size-fits-all approach,' Harclerode said. Are you getting the most out of your employer-sponsored pharmacy benefits? From pricing terms and contracts to understanding clinical programs, Holmes Murphy can help. As one of the largest independent insurance brokerages in the nation, Holmes Murphy believes fully in serving the unique risk and benefits challenges of clients in every industry and of almost every size. For more information, visit or follow the company on X (@holmesmurphyins), Facebook, LinkedIn, or Instagram.

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

Indianapolis Star

time3 hours ago

  • Indianapolis Star

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration. 'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.' PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026. 'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.' Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are: US-based Investors: 1-877-407-0752 International Investors: 1-201-389-0912 Conference Call ID: 13754335 The webcast link for the event can be found here: A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event. About Protagonist Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin. More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors cdavis@ +1 212 915 2577 Media Relations Contact Virginia Amann ENTENTE Network of Companies virginiaamann@ +1 833 500 0061 ext. 1 SOURCE: Protagonist Therapeutics View the original press release on ACCESS Newswire

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Business Upturn

time8 hours ago

  • Business Upturn

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store